Reduced Endothelium-Dependent Vasodilation in T2DM

Share this content:
Reduced Endothelium-Dependent Vasodilation in T2DM
Reduced Endothelium-Dependent Vasodilation in T2DM

TUESDAY, Feb. 21, 2017 (HealthDay News) -- Patients with type 2 diabetes have reduced endothelium-dependent vasodilation, regardless of the presence of polyneuropathy, according to a study published online Feb. 15 in Diabetes Care.

Anna L. Emanuel, from the VU University Medical Center in Amsterdam, and colleagues compared skin microvascular function in 16 healthy controls (HCs), 16 patients with cryptogenic axonal polyneuropathy (CAP), 15 patients with type 2 diabetes with polyneuropathy (DPN), and 11 patients with type 2 diabetes without polyneuropathy. Skin biopsy and nerve conduction studies were used to assess axonal degeneration.

The researchers found that, compared with HCs, patients with CAP and DPN demonstrated a similar decrease in intraepidermal nerve fiber density and sural sensory nerve action potential. Compared with HCs, patients with CAP had a similar vasodilator response to acetylcholine (relative mean difference based on log values, 13.3 percent; P = 0.652), but patients with diabetes, with and without neuropathy, had lower response (157.5 and 174.2 percent; both P = 0.003). There were no significant differences between the patient groups with diabetes (P = 0.845). The vasodilator response to sodium nitroprusside did not differ significantly among the groups (P = 0.0802).

"These data suggest that in type 2 diabetes, neuropathy does not contribute to impaired microvascular endothelium-dependent vasodilation and vice versa," the authors write.

One author is an employee of Biogen, which funded the study.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »